DFX Intelligence

Data Factory

Private creditBorrowerpharmaceuticalsaunknown

Nephron Pharmaceuticals Corp. et al

Private Credit

Search this name across graphsid dfx:pc:21fa7ec9-5130-dc1a-ac7a-e67392ddee69

Data as of Sep 30, 2024 (this record's last observation) from The BDC tape; Adviser-reported credit funds; Deal parties; Pending. Page built Sep 19, 2026, 10:01 AM UTC and rebuilt at most every 15 minutes.

Relationships: 0
Dated events: 40
On other graphs: 0
Observed: Sep 30, 2023 to Sep 30, 2024
6 observations

Across DFX

This entity has not been resolved onto another DFX graph by a shared identifier. A name match elsewhere would be a candidate, never an identity, and none is recorded.

Facts

fact = as filed or announced; derived = computed by DFX; estimate = a band, never a point

Lenders: 4
BDCs: 3
Facilities: 1
Principal, latest: $43.3Mpieces as filed; a lower bound
Fair value, latest: $40.3M
Mark ratio: 97%fair value over cost, latest
Next maturity: Sep 11, 2026
First on a schedule: Sep 30, 2023
Last on a schedule: Sep 30, 2024

Facilities

one facility is one borrower, one kind and one lien; its size is the sum of the BDC pieces the tape can see, a lower bound, never the commitment

Kind	Lien	Size, lower bound	Fair value	Maturity	Maturity basis	Spread	PIK	Lenders	BDCs	Status	Last seen
Term loan	First lien	$43.3M	$40.3M	Sep 11, 2026	Xbrl fact	0	0	3	4	Unknown	Sep 30, 2024

Lenders holding it now

each BDC's own pieces on its latest schedule, folded to one row per lender; every amount is that BDC's piece as filed, so a sum is a lower bound

BDC	Pieces	Principal	Fair value	Unfunded	Nearest maturity	As of
BlackRock Capital Investment Corp	1	$4.5M	$3.9M	$0	Sep 11, 2026	Dec 31, 2023

Relationships

No published relationship touches this entity yet.

Dated events

13 bookkeeping events (roster, classification and holdings changes) folded below

Occurred
Sep 30, 2024
Mark recovered
Nephron Pharmaceuticals Corp. et al term loan: marked from 88 to 97 cents on cost
BDC schedule of investments
$43.3M
Occurred
Sep 30, 2024
Borrower left every BDC schedule
Nephron Pharmaceuticals Corp. et al term loan (first lien) left every BDC schedule after 2024-09-30 (4 lenders, $43.3M last held)
BDC schedule of investments
$43.3M
Occurred
Sep 30, 2024
BDC left a facility
BlackRock Direct Lending Corp. no longer holds Nephron Pharmaceuticals Corp. et al term loan after 2024-09-30; 1 BDC(s) still hold it
BDC schedule of investments
$4.3M
Occurred
Sep 30, 2024
Spread increased
BlackRock TCP Capital Corp.: spread increased in Nephron Pharmaceuticals Corp. et al (11.16% to 20.00%)
BDC schedule of investmentsobserved 1.9 years ago
0.2 usd
Occurred
Sep 30, 2024
Mark recovered
BlackRock Direct Lending Corp.: fair value recovery in Nephron Pharmaceuticals Corp. et al (87 to 96 cents on cost)
BDC schedule of investmentsobserved 1.9 years ago
0.957299155308329 usd
Occurred
Sep 30, 2024
Mark recovered
BlackRock TCP Capital Corp.: fair value recovery in Nephron Pharmaceuticals Corp. et al (88 to 97 cents on cost)
BDC schedule of investmentsobserved 1.9 years ago
0.969896416483357 usd
Occurred
Sep 30, 2024
Mark recovered
BlackRock Private Credit Fund: fair value recovery in Nephron Pharmaceuticals Corp. et al (87 to 96 cents on cost)
BDC schedule of investmentsobserved 1.9 years ago
0.957709818851725 usd
Occurred
Sep 30, 2024
BDC left a facility
BlackRock TCP Capital Corp. no longer holds Nephron Pharmaceuticals Corp. et al term loan after 2024-09-30; 1 BDC(s) still hold it
BDC schedule of investments
$29.5M
Occurred
Sep 30, 2024
BDC left a facility
BlackRock Private Credit Fund no longer holds Nephron Pharmaceuticals Corp. et al term loan after 2024-09-30; 1 BDC(s) still hold it
BDC schedule of investments
$9.5M
Occurred
Jun 30, 2024
Marked down across lenders
Nephron Pharmaceuticals Corp. et al term loan: marked from 94 to 88 cents on cost across 3 lender(s)
BDC schedule of investments
$43.4M
Occurred
Jun 30, 2024
PIK interest added
Nephron Pharmaceuticals Corp. et al term loan: PIK interest of 20.00% appears (was cash pay)
BDC schedule of investments
$43.4M
Occurred
Jun 30, 2024
Coupon changed
Nephron Pharmaceuticals Corp. et al term loan: spread moved from 9.00% to 11.16%
BDC schedule of investments
$43.4M
Occurred
Jun 30, 2024
Marked down by a BDC
BlackRock TCP Capital Corp.: fair value markdown in Nephron Pharmaceuticals Corp. et al (95 to 88 cents on cost)
BDC schedule of investmentsobserved 2.1 years ago
0.882696947654303 usd
Occurred
Jun 30, 2024
Marked down by a BDC
BlackRock Private Credit Fund: fair value markdown in Nephron Pharmaceuticals Corp. et al (93 to 87 cents on cost)
BDC schedule of investmentsobserved 2.1 years ago
0.868267929181169 usd
Occurred
Jun 30, 2024
Spread increased
BlackRock TCP Capital Corp.: spread increased in Nephron Pharmaceuticals Corp. et al (9.00% to 11.16%)
BDC schedule of investmentsobserved 2.1 years ago
0.1116 usd
Occurred
Jun 30, 2024
Spread increased
BlackRock Direct Lending Corp.: spread increased in Nephron Pharmaceuticals Corp. et al (9.00% to 11.16%)
BDC schedule of investmentsobserved 2.1 years ago
0.1116 usd
Occurred
Jun 30, 2024
Spread increased
BlackRock Private Credit Fund: spread increased in Nephron Pharmaceuticals Corp. et al (9.00% to 11.16%)
BDC schedule of investmentsobserved 2.1 years ago
0.1116 usd
Occurred
Jun 30, 2024
Marked down by a BDC
BlackRock Direct Lending Corp.: fair value markdown in Nephron Pharmaceuticals Corp. et al (93 to 87 cents on cost)
BDC schedule of investmentsobserved 2.1 years ago
0.870043811253607 usd
Occurred
Jun 30, 2024
PIK interest added
BlackRock Private Credit Fund: pik added in Nephron Pharmaceuticals Corp. et al (0.00% to 20.00%)
BDC schedule of investmentsobserved 2.1 years ago
0.2 usd
Occurred
Jun 30, 2024
PIK interest added
BlackRock Direct Lending Corp.: pik added in Nephron Pharmaceuticals Corp. et al (0.00% to 20.00%)
BDC schedule of investmentsobserved 2.1 years ago
0.2 usd
Occurred
Jun 30, 2024
PIK interest added
BlackRock TCP Capital Corp.: pik added in Nephron Pharmaceuticals Corp. et al (0.00% to 20.00%)
BDC schedule of investmentsobserved 2.1 years ago
0.2 usd
Occurred
Dec 31, 2023
Marked down across lenders
Nephron Pharmaceuticals Corp. et al term loan: marked from 100 to 90 cents on cost across 4 lender(s)
BDC schedule of investments
$54.5M
Occurred
Dec 31, 2023
Marked down by a BDC
BlackRock Private Credit Fund: fair value markdown in Nephron Pharmaceuticals Corp. et al (100 to 90 cents on cost)
BDC schedule of investmentsobserved 1.6 years ago
0.897221365394678 usd
Occurred
Dec 31, 2023
Marked down by a BDC
BlackRock Capital Investment Corp: fair value markdown in Nephron Pharmaceuticals Corp. et al (100 to 90 cents on cost)
BDC schedule of investmentsobserved 2.5 years ago
0.89795237219566 usd
Occurred
Dec 31, 2023
Marked down by a BDC
BlackRock Direct Lending Corp.: fair value markdown in Nephron Pharmaceuticals Corp. et al (100 to 90 cents on cost)
BDC schedule of investmentsobserved 1.6 years ago
0.897952261245794 usd
Occurred
Dec 31, 2023
Marked down by a BDC
BlackRock TCP Capital Corp.: fair value markdown in Nephron Pharmaceuticals Corp. et al (100 to 90 cents on cost)
BDC schedule of investmentsobserved 1.6 years ago
0.897952363259634 usd
Occurred
Sep 30, 2023
Borrower first appears on a BDC schedule
Nephron Pharmaceuticals Corp. et al first appears in a BDC schedule (4 lenders)
BlackRock TCP Capital Corp.BDC schedule of investmentsobserved 2.9 years ago
$41.4M

Show 13 bookkeeping events

Occurred
Dec 31, 2024
BlackRock Private Credit Fund: position exited in Nephron Pharmaceuticals Corp. et al ($9.5M principal)
Occurred
Dec 31, 2024
BlackRock Direct Lending Corp.: position exited in Nephron Pharmaceuticals Corp. et al ($4.3M principal)
Occurred
Dec 31, 2024
BlackRock TCP Capital Corp.: position exited in Nephron Pharmaceuticals Corp. et al ($29.5M principal)
Occurred
Jun 30, 2024
BlackRock Private Credit Fund: principal increased in Nephron Pharmaceuticals Corp. et al ($9.5M principal)
Occurred
Jun 30, 2024
BlackRock TCP Capital Corp.: principal increased in Nephron Pharmaceuticals Corp. et al ($29.6M principal)
Occurred
Mar 31, 2024
BlackRock TCP Capital Corp.: principal increased in Nephron Pharmaceuticals Corp. et al ($28.1M principal)
Occurred
Mar 31, 2024
BlackRock Direct Lending Corp.: principal decreased in Nephron Pharmaceuticals Corp. et al ($4.1M principal)
Occurred
Mar 31, 2024
BlackRock Private Credit Fund: principal decreased in Nephron Pharmaceuticals Corp. et al ($9.0M principal)
Occurred
Dec 31, 2023
BlackRock Private Credit Fund: principal increased in Nephron Pharmaceuticals Corp. et al ($18.2M principal)
Occurred
Dec 31, 2023
BlackRock Direct Lending Corp.: principal increased in Nephron Pharmaceuticals Corp. et al ($8.2M principal)
Occurred
Sep 30, 2023
BlackRock Capital Investment Corp: new position in Nephron Pharmaceuticals Corp. et al ($4.5M principal)
Occurred
Sep 30, 2023
BlackRock Private Credit Fund: new position in Nephron Pharmaceuticals Corp. et al ($9.1M principal)
Occurred
Sep 30, 2023
BlackRock Direct Lending Corp.: new position in Nephron Pharmaceuticals Corp. et al ($4.1M principal)

Provenance

Graph: Private Credit
Canonical id: dfx:pc:21fa7ec9-5130-dc1a-ac7a-e67392ddee69
First observed: Sep 30, 2023
Last observed: Sep 30, 2024 23 months ago
Resolution: Identity across graphs by shared identifier (CRD, CIK, EIN, ADV fund id, individual CRD) or citation; a name match is shown as a candidate and never merged.

Nephron Pharmaceuticals Corp. et al

Private Credit

Search this name across graphsid dfx:pc:21fa7ec9-5130-dc1a-ac7a-e67392ddee69

Kind

Lien

Size, lower bound

Fair value

Maturity

Maturity basis

Spread

PIK

Lenders

BDCs

Status

Last seen

Term loan

First lien

$43.3M

$40.3M

Sep 11, 2026

Xbrl fact

Unknown

Sep 30, 2024

BDC

Pieces

Principal

Fair value

Unfunded

Nearest maturity

As of

BlackRock Capital Investment Corp

$4.5M

$3.9M

Sep 11, 2026

Dec 31, 2023